Have you been wondering about CAR T cells and lupus? Fate Therapeutics Inc. is excited to share that we’ve started an iPSC-derived CAR T cell program for patients with active lupus. To learn more visit: Study Details | FT819 in Moderate to Severe Active Systemic Lupus Erythematosus | https://lnkd.in/gaDGjYCv
Fate Therapeutics Inc.
Biotechnology Research
San Diego, California 21,381 followers
Transforming the lives of patients with cancer and autoimmune diseases.
About us
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
- Website
-
http://www.fatetherapeutics.com
External link for Fate Therapeutics Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2007
- Specialties
- stem cells, stem cell modulators, iPS cells, iPSCs, T Cells, NK Cells, CAR T, Cell Therapy, Pluripotent Stem Cells, Off-the-Shelf, autoimmune disorders, and immuno-oncology
Locations
-
Primary
Get directions
12278 Scripps Summit Dr
San Diego, California 92131, US
Employees at Fate Therapeutics Inc.
-
Cindy Robinson Tahl
General Counsel and Corporate Secretary at Fate Therapeutics Inc
-
Jon Rosen
Sr. Director, Research & Technology Core at Fate Therapeutics Inc
-
Mike Sonnenberg
Vice President Quality Control at Fate Therapeutics
-
Jim Beitel
Senior Vice President Of Corporate Development at Fate Therapeutics Inc
Updates
-
Fate Therapeutics Inc. was proud to recognize Mental Health Awareness Month by hosting an uplifting all-company luncheon! Joined by our partners from Cigna Healthcare and Marsh McLennan, we shared information about the many mental health and wellness resources nestled within our benefits plan, including access to Headspace, Talkspace, and Happify. We enjoyed fresh food followed by friendly matches in our Game Area and patio to revitalize our spirits. Our Exos fitness center yoga instructor shared mindfulness and relaxation tips, guiding our team as they crafted their own essential oil blends in the Fate Zen Den. Here’s to fostering a culture of well-being and support! #MentalHealthMatters #EmployeeWellness
-
-
-
-
-
+3
-
-
This week we announced pricing of $100M in financing!
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
ir.fatetherapeutics.com
-
Fate Therapeutics Inc was proud to sponsor and join patients, caregivers, and supporters at The Leukemia & Lymphoma Society's Light The Night Walk in San Diego on November 4th. Through bake sales and donations, Team Fate united to raise funds to support research and treatment for patients with blood cancers. Together we bring light to the darkness of cancer. #lightthenight #cancerresearch
-
-
-
-
-
+1
-
-
The Fate Therapeutics Team came together to embrace the spirit of competition and camaraderie on our annual Field Day. Through sports challenges and friendly contests, we celebrated our collective strength and the bond that fuels our shared journey. Then we cooled down at the Science Fair where our R&D and Clinical team members shared posters that they presented at the latest scientific conferences. Through triumphs and challenges, we stand strong, pushing forward with a collective determination that fuels our mission to transform the lives of patients with cancer and autoimmune disorders.
-
-
-
-
-
+3
-